Literature DB >> 29096967

Hepatocellular carcinoma: Present and future.

Carolina Armengol1, Maria Rosa Sarrias2, Margarita Sala3.   

Abstract

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide with over 740,000 new cases per year and the third leading cause of cancer-related death, with a growing incidence in recent years. This tumor usually arises in patients with an underlying chronic liver disease. The management of this tumor has improved over the past 2 decades: patients at risk are included in a surveillance program, a prognostic staging system has been created and, finally, new treatments particularly aimed at patients with advanced HCC have been developed. This fact has resulted in a greater interest in this tumor and several scientific societies have developed clinical practice guidelines for the management of patients with this disease. In this article, we review the current and future prospects of this tumor.
Copyright © 2017 Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Carcinoma hepatocelular; Hepatocellular carcinoma; Liver transplant; Radioembolización; Radioembolization; Regorafenib; Sorafenib; Trasplante hepático

Mesh:

Substances:

Year:  2017        PMID: 29096967     DOI: 10.1016/j.medcli.2017.08.010

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  21 in total

1.  Axis inhibition protein 1 (Axin1) Deletion-Induced Hepatocarcinogenesis Requires Intact β-Catenin but Not Notch Cascade in Mice.

Authors:  Yu Qiao; Jingxiao Wang; Eylul Karagoz; Binyong Liang; Xinhua Song; Runze Shang; Katja Evert; Meng Xu; Li Che; Matthias Evert; Diego F Calvisi; Junyan Tao; Bruce Wang; Satdarshan P Monga; Xin Chen
Journal:  Hepatology       Date:  2019-04-11       Impact factor: 17.425

2.  CircMYH9 increases KPNA2 mRNA stability to promote hepatocellular carcinoma progression in an EIF4A3-dependent manner.

Authors:  Jinguo Xia; Chen Wu; Yanhui Tang; Junwei Tang; Deming Zhu; Feihong Zhang; Zhenggang Xu; Dongwei Sun; Zhongming Tan; Han Zhuo
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

3.  ROS-Mediated Anti-Tumor Effect of Coptidis Rhizoma against Human Hepatocellular Carcinoma Hep3B Cells and Xenografts.

Authors:  So Young Kim; Cheol Park; Min Yeong Kim; Seon Yeong Ji; Hyun Hwangbo; Hyesook Lee; Su Hyun Hong; Min Ho Han; Jin-Woo Jeong; Gi-Young Kim; Chang-Gue Son; JaeHun Cheong; Yung Hyun Choi
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

4.  Characteristics of Newly Diagnosed Hepatocellular Carcinoma Patients Across Turkey: Prospective Multicenter Observational 3K Registry Study.

Authors:  Ulus Salih Akarca; Belkis Unsal; Orhan Sezgin; Kendal Yalcin; Meral Akdogan; Can Gonen; Feyza Gunduz; Seren Ozenirler; Abdullah Sonsuz; Dinc Dincer; Salim Basol Tekin; Idris Yucel; Hakan Akbulut; Canan Alkım; Ozgur Ozyilkan; Arzu Baygul; Zeynep Merve Cevik; Ramazan Idilman; On Behalf Of K Registry Study Group
Journal:  Turk J Gastroenterol       Date:  2021-12       Impact factor: 1.555

5.  Construction and Characterization of Adenovirus Vectors Encoding Aspartate-β-Hydroxylase to Preliminary Application in Immunotherapy of Hepatocellular Carcinoma.

Authors:  Yujiao Zhou; Feifei Liu; Chengmin Li; Guo Shi; Xiaolei Xu; Xue Luo; Yuanling Zhang; Jingjie Fu; Aizhong Zeng; Limin Chen
Journal:  J Immunol Res       Date:  2018-07-15       Impact factor: 4.818

6.  CalliSpheres Drug-Eluting Bead Transcatheter Arterial Chemoembolization Presents With Better Efficacy and Equal Safety Compared to Conventional TACE in Treating Patients With Hepatocellular Carcinoma.

Authors:  Hua Xiang; Lin Long; Yuanhui Yao; Zhiyong Fang; Zhiming Zhang; Yongjin Zhang
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

7.  LncRNA KCNQ1OT1 inhibits the radiosensitivity and promotes the tumorigenesis of hepatocellular carcinoma via the miR-146a-5p/ACER3 axis.

Authors:  Ganghua Yang; Lijing Zhou; Qinhong Xu; Fandi Meng; Yong Wan; Xiankui Meng; Lin Wang; Lei Zhang
Journal:  Cell Cycle       Date:  2020-09-16       Impact factor: 4.534

8.  Crizotinib and Doxorubicin Cooperatively Reduces Drug Resistance by Mitigating MDR1 to Increase Hepatocellular Carcinoma Cells Death.

Authors:  Ming Shao; Run Shi; Zhen-Xing Gao; Shan-Shan Gao; Jing-Feng Li; Huan Li; Shu-Zhong Cui; Wei-Min Hu; Tian-Yun Chen; Gui-Ru Wu; Jie Zhang; Jiang Xu; Man-Sun Sy; Chaoyang Li
Journal:  Front Oncol       Date:  2021-05-18       Impact factor: 6.244

9.  Long noncoding RNA SLC2A1-AS1 regulates aerobic glycolysis and progression in hepatocellular carcinoma via inhibiting the STAT3/FOXM1/GLUT1 pathway.

Authors:  Runze Shang; Miao Wang; Bin Dai; Jianbing Du; Jianlin Wang; Zekun Liu; Shibin Qu; Xisheng Yang; Jingjing Liu; Congcong Xia; Lin Wang; Desheng Wang; Yu Li
Journal:  Mol Oncol       Date:  2020-03-30       Impact factor: 6.603

Review 10.  Liver Cancer: Current and Future Trends Using Biomaterials.

Authors:  Sue Anne Chew; Stefania Moscato; Sachin George; Bahareh Azimi; Serena Danti
Journal:  Cancers (Basel)       Date:  2019-12-16       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.